Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

4.525 +0.025 (+0.56%)
Streaming Delayed Price Updated: 11:51 AM EDT, Jun 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 230,452
Open 4.410
Bid (Size) 4.520 (600)
Ask (Size) 4.530 (700)
Prev. Close 4.500
Today's Range 4.390 - 4.615
52wk Range 3.530 - 8.590
Shares Outstanding 93,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy

Performance

YTD
-26.3%
-26.3%
1 Month
+17.5%
+17.5%
3 Month
-2.9%
-2.9%
6 Month
-33.1%
-33.1%
1 Year
-6.9%
-6.9%

More News

Read More
News headline image
3 High-Flying Stocks We’re Skeptical Of
Via StockStory
News headline image
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS ↗
Via Chartmill
Topics Earnings
News headline image
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Unprofitable Stock to Consider Right Now and 2 We Turn Down
Via StockStory
Topics Energy
News headline image
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
3 of Wall Street’s Favorite Stocks with Open Questions
Via StockStory
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins
Via StockStory
News headline image
Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%
Via StockStory
News headline image
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Small-Cap Stocks We Think Twice About
Via StockStory
News headline image
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Cash-Burning Stock to Target This Week and 2 We Question
Via StockStory
News headline image
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
3 Healthcare Stocks with Open Questions
Via StockStory

Frequently Asked Questions

Is Myriad Genetics, Inc. - Common Stock publicly traded?
Yes, Myriad Genetics, Inc. - Common Stock is publicly traded.
What exchange does Myriad Genetics, Inc. - Common Stock trade on?
Myriad Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Myriad Genetics, Inc. - Common Stock?
The ticker symbol for Myriad Genetics, Inc. - Common Stock is MYGN on the Nasdaq Stock Market
What is the current price of Myriad Genetics, Inc. - Common Stock?
The current price of Myriad Genetics, Inc. - Common Stock is 4.525
When was Myriad Genetics, Inc. - Common Stock last traded?
The last trade of Myriad Genetics, Inc. - Common Stock was at 06/23/26 11:51 AM ET
What is the market capitalization of Myriad Genetics, Inc. - Common Stock?
The market capitalization of Myriad Genetics, Inc. - Common Stock is 423.09M
How many shares of Myriad Genetics, Inc. - Common Stock are outstanding?
Myriad Genetics, Inc. - Common Stock has 423M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.